BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 29467338)

  • 41. Regulation of DNA Damage Signaling and Cell Death Responses by Epstein-Barr Virus Latent Membrane Protein 1 (LMP1) and LMP2A in Nasopharyngeal Carcinoma Cells.
    Wasil LR; Wei L; Chang C; Lan L; Shair KH
    J Virol; 2015 Aug; 89(15):7612-24. PubMed ID: 25972552
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tax and M1 peptide/HLA-A2-specific Fabs and T cell receptors recognize nonidentical structural features on peptide/HLA-A2 complexes.
    Biddison WE; Turner RV; Gagnon SJ; Lev A; Cohen CJ; Reiter Y
    J Immunol; 2003 Sep; 171(6):3064-74. PubMed ID: 12960332
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dendritic cells for the induction of EBV immunity.
    Subklewe M
    Recent Results Cancer Res; 2002; 159():38-43. PubMed ID: 11785842
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Recognition of autologous lymphoblastoid cells by cloned human T cells: inhibition of cytotoxicity by anti-HLA antibody but not by antibody to Epstein-Barr virus induced cell surface antigen.
    Hank JA; Sondel PM
    Hum Immunol; 1984 Apr; 9(4):211-9. PubMed ID: 6201468
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Delayed-type hypersensitivity (DTH) immune response related with EBV-DNA in nasopharyngeal carcinoma treated with autologous dendritic cell vaccination after radiotherapy.
    Li F; Song D; Lu Y; Zhu H; Chen Z; He X
    J Immunother; 2013 Apr; 36(3):208-14. PubMed ID: 23502768
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Development of a T-cell Receptor Mimic Antibody against Wild-Type p53 for Cancer Immunotherapy.
    Li D; Bentley C; Anderson A; Wiblin S; Cleary KLS; Koustoulidou S; Hassanali T; Yates J; Greig J; Nordkamp MO; Trenevska I; Ternette N; Kessler BM; Cornelissen B; Cragg MS; Banham AH
    Cancer Res; 2017 May; 77(10):2699-2711. PubMed ID: 28363997
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Detection and analysis of anti-latent membrane protein 2A antibodies in the sera of patients with Epstein-Barr virus associated malignancies.
    Chen Y; Yao K; Sun H; Qing J; Peng GY
    Chin Med J (Engl); 2005 May; 118(9):725-30. PubMed ID: 15899133
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The generation of LMP2a-specific cytotoxic T lymphocytes for the treatment of patients with Epstein-Barr virus-positive Hodgkin disease.
    Su Z; Peluso MV; Raffegerst SH; Schendel DJ; Roskrow MA
    Eur J Immunol; 2001 Mar; 31(3):947-58. PubMed ID: 11241300
    [TBL] [Abstract][Full Text] [Related]  

  • 49. EBV LMP2A-specific T cell immune responses elicited by dendritic cells loaded with LMP2A protein.
    Chen Y; Sun H; Liu G; Wang B; Wang F; Sun B; Yao K
    Cell Mol Immunol; 2009 Aug; 6(4):269-76. PubMed ID: 19728928
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mouse model of Epstein-Barr virus LMP1- and LMP2A-driven germinal center B-cell lymphoproliferative disease.
    Minamitani T; Ma Y; Zhou H; Kida H; Tsai CY; Obana M; Okuzaki D; Fujio Y; Kumanogoh A; Zhao B; Kikutani H; Kieff E; Gewurz BE; Yasui T
    Proc Natl Acad Sci U S A; 2017 May; 114(18):4751-4756. PubMed ID: 28351978
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.
    Roychowdhury S; Baiocchi RA; Vourganti S; Bhatt D; Blaser BW; Freud AG; Chou J; Chen CS; Xiao JJ; Parthun M; Chan KK; Eisenbeis CF; Ferketich AK; Grever MR; Chen CS; Caligiuri MA
    J Natl Cancer Inst; 2004 Oct; 96(19):1447-57. PubMed ID: 15467034
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The effects of the Epstein-Barr virus latent membrane protein 2A on B cell function.
    Merchant M; Swart R; Katzman RB; Ikeda M; Ikeda A; Longnecker R; Dykstra ML; Pierce SK
    Int Rev Immunol; 2001; 20(6):805-35. PubMed ID: 11913951
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Selective targeting of melanoma and APCs using a recombinant antibody with TCR-like specificity directed toward a melanoma differentiation antigen.
    Denkberg G; Lev A; Eisenbach L; Benhar I; Reiter Y
    J Immunol; 2003 Sep; 171(5):2197-207. PubMed ID: 12928363
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Detection of wild type and deleted latent membrane protein 1 (LMP1) of Epstein-Barr virus in clinical biopsy material.
    Nicholls J; Hahn P; Kremmer E; Fröhlich T; Arnold GJ; Sham J; Kwong D; Grässer FA
    J Virol Methods; 2004 Mar; 116(1):79-88. PubMed ID: 14715310
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Specificity of T cells in synovial fluid: high frequencies of CD8(+) T cells that are specific for certain viral epitopes.
    Tan LC; Mowat AG; Fazou C; Rostron T; Roskell H; Dunbar PR; Tournay C; Romagné F; Peyrat MA; Houssaint E; Bonneville M; Rickinson AB; McMichael AJ; Callan MF
    Arthritis Res; 2000; 2(2):154-64. PubMed ID: 11062606
    [TBL] [Abstract][Full Text] [Related]  

  • 56. CD4+ T cell responses in the immune control against latent infection by Epstein-Barr virus.
    Paludan C; Münz C
    Curr Mol Med; 2003 Jun; 3(4):341-7. PubMed ID: 12776989
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Combination of Epstein-Barr virus nuclear antigen 1, 3 and lytic antigen BZLF1 peptide pools allows fast and efficient stimulation of Epstein-Barr virus-specific T cells for adoptive immunotherapy.
    Wang Y; Aïssi-Rothe L; Virion JM; De Carvalho Bittencourt M; Ulas N; Audonnet S; Salmon A; Clement L; Venard V; Jeulin H; Stoltz JF; Decot V; Bensoussan D
    Cytotherapy; 2014 Jan; 16(1):122-34. PubMed ID: 24094498
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Loss of T-Cell Multifunctionality and TCR-Vβ Repertoire Against Epstein-Barr Virus Is Associated With Worse Prognosis and Clinical Parameters in HIV
    Hernández DM; Valderrama S; Gualtero S; Hernández C; López M; Herrera MV; Solano J; Fiorentino S; Quijano S
    Front Immunol; 2018; 9():2291. PubMed ID: 30337929
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma.
    Straathof KC; Leen AM; Buza EL; Taylor G; Huls MH; Heslop HE; Rooney CM; Bollard CM
    J Immunol; 2005 Sep; 175(6):4137-47. PubMed ID: 16148164
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Selection of a Clinical Lead TCR Targeting Alpha-Fetoprotein-Positive Liver Cancer Based on a Balance of Risk and Benefit.
    Luo X; Cui H; Cai L; Zhu W; Yang WC; Patrick M; Zhu S; Huang J; Yao X; Yao Y; He Y; Ji Y
    Front Immunol; 2020; 11():623. PubMed ID: 32425926
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.